Retinal Diseases: Recent Advances in Diagnosis and Treatment

Dear Colleagues,

In recent years, we have witnessed significant advances in the diagnosis and treatment of retinal diseases. These advances have been made possible by the development of novel imaging technologies, such as optical coherence tomography (OCT) and angiography, which enable the detailed visualization of the retina. In addition, there have been major advances in the development of novel drugs and gene therapies for retinal diseases.

Some of the recent advances in the diagnosis and treatment of retinal diseases include the following:

• The development of new imaging technologies, such as OCT and angiography, which enable the detailed visualization of the retina.
• The development of new drugs, such as anti-vascular endothelial growth factor (VEGF) drugs, which can be employed to treat wet age-related macular degeneration (AMD).
• The development of gene therapies, such as Luxturna®, which can be used to treat inherited retinal diseases.

These advances have led to improved outcomes for patients with retinal diseases. However, there is still much to be achieved in the field. This Special Issue in the Journal of Clinical & Translational Ophthalmology, focusing on retinal diseases, will connect leading experts in the field to discuss the latest advances in this area. The articles in this Special Issue will provide valuable insights into the potential of these advances to improve the diagnosis and treatment of retinal diseases.

Dr. Dario Giorgio
Dr. Dario Pasquale Mucciolo
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical & Translational Ophthalmology is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• retinal diseases
• retinal degeneration
• macular degeneration
• OCT
• retinal imaging